AZ628

AZ628 is a potent, ATP-competitive small molecule inhibitor of Raf kinases, including B-Raf, B-Raf V600E, and C-Raf. It was developed by AstraZeneca as a targeted therapy to inhibit the MAPK/ERK signaling pathway, which is frequently dysregulated in various malignancies. While AZ628 has demonstrated significant preclinical activity in inhibiting the proliferation of BRAF-mutant melanoma and non-small cell lung cancer (NSCLC) cell lines, it is primarily utilized as a pharmacological research tool rather than a clinical candidate. Research involving AZ628 often focuses on understanding the molecular mechanisms of drug resistance and the behavior of drug-tolerant persister cells in cancer.